1 MTN-003 Study Specific Training Randomization Overview.

Slides:



Advertisements
Similar presentations
Pharmacology and the Nursing Process in LPN Practice
Advertisements

1 US Investigator Meeting DIAS-4, Chicago, July 2011 Good Clinical Practice (GCP) for Investigators and the Research Team.
1 US Investigator Meeting DIAS-4, Chicago, July 2011 Informed Consent.
1 Copyright © 2010, Elsevier Inc. All rights Reserved Fig 2.1 Chapter 2.
By D. Fisher Geometric Transformations. Reflection, Rotation, or Translation 1.
Labeling claims for patient- reported outcomes (A regulatory perspective) FDA/Industry Workshop Washington, DC September 16, 2005 Lisa A. Kammerman, Ph.D.
Document #07-12G 1 RXQ Customer Enrollment Using a Registration Agent Process Flow Diagram (Switch) Customer Supplier Customer authorizes Enrollment.
Document #07-12G 1 RXQ Customer Enrollment Using a Registration Agent Process Flow Diagram (Switch) Customer Supplier Customer authorizes Enrollment.
1 Welcome Safety Regulatory Function Handbook April 2006.
Business Transaction Management Software for Application Coordination 1 Business Processes and Coordination.
HIV Drug Resistance Training
Jeopardy Q 1 Q 6 Q 11 Q 16 Q 21 Q 2 Q 7 Q 12 Q 17 Q 22 Q 3 Q 8 Q 13
Jeopardy Q 1 Q 6 Q 11 Q 16 Q 21 Q 2 Q 7 Q 12 Q 17 Q 22 Q 3 Q 8 Q 13
Title Subtitle.
GOALS FOR TODAY Understand how to write a HACCP Plan
Performance Review 101 A Guide to the Alaska Teacher Performance Review 1.
Fall HSGQE Retest District Test Coordinator Training September 18-19, 2008.
RWM SBA (Grades 3-9) Science SBA (Grades 4 8, & 10) Test Administrator
606 CMR 14.00: Background Record Checks What you need to know!
0 - 0.
1 ICOTS (Interstate Compact Offender Tracking System) Attachments Training.
DIVIDING INTEGERS 1. IF THE SIGNS ARE THE SAME THE ANSWER IS POSITIVE 2. IF THE SIGNS ARE DIFFERENT THE ANSWER IS NEGATIVE.
Addition Facts
Spring 2013 Florida Alternate Assessment Test Coordinator Responsibilities Lake County Schools Tonya Mass Testing Program Specialist 1.
ZMQS ZMQS
1 MTN-003 Training Follow-up Visit Scheduling and Visit Coding SSP Sections and
1 SLIDE Insurance Company Regulation Division Insurance Market Regulation Division Medical Professional Liability Insurance Claim Reports Online Claim.
CROMS NIDCR Clinical Monitoring
RFT Evaluation of clinical interventions in community pharmacy Final Report This project was funded by the Australian Government Department of.
Software change management
CCHSA Accreditation: New Standards for Managing Medications
AS9102 First Article Inspection Report
HIV Counseling &Testing. Page 346 HIV and Risk Reduction (RR) Counseling Required at all scheduled visits Includes HIV Pre- and Post-test counseling.
Senate Bill 638- assess English Learners to determine English Language Proficiency CELDT - designated test Initial Assessment Testing the first time for.
ASPIRE TRAINING RANDOMIZATION & INITIAL DISPENSING Cindy Jacobson, PharmD (MTN) Jen Berthiaume/Missy Cianciola (SCHARP)
Checking & Corrective Action
Addition 1’s to 20.
25 seconds left…...
Week 1.
Quality Auditing Dr Alan G Rowley
Unit 4: Specimen and Data Collection # Warm Up Questions: Instructions  Take five minutes now to try the Unit 4 warm up questions in your manual.
We will resume in: 25 Minutes.
1 MTN-003 Training Specimen Labeling and Preparation for Entry into LDMS.
Study Product Adherence Counseling At Enrollment MTN-003 Study-Specific Training.
Developed by Klinikos; Roy Fraser (2012) Investigator Study File
1 MTN 003 Data Management Considerations SSP Sections 14, 15 & 17.
ASPIRE TRAINING Study Product Considerations & Accountability for Non-Pharmacy Staff.
MTN-028 Study Product Considerations Cindy Jacobson Lindsay Kramzer Microbicide Trials Network.
Coordinator University Clinical Research Pharmacy Investigational Drug Service (IDS) Marjorie Shaw Phillips, MS, RPh, FASHP Clinical Research Pharmacist.
MTN-027 Study Product Considerations Cindy Jacobson Microbicide Trials Network Pittsburgh, PA USA.
Joint Research & Enterprise Office Training The team, the procedures, the monitor and the Sponsor Lucy H H Parker Clinical Research Governance Manager.
Overview of Enrollment Procedures. Training Materials for this session  All materials for this session can be found under the Enrollment tab of your.
Informed Consent Process: Key Considerations. Introduction  Informed consent is a requirement of ethical clinical research  Section 4.8 of the International.
Study Product Return Re-Supply and Re-Issue MTN-003 Study-Specific Training.
**INSERT YOUR TITLE HERE**
RIHES-II: H ANDLING A UDITS AND I NSPECTIONS E FFECTIVE D ATE 25 D ECEMBER 2006 V ERSION : 3.0 บุญเหลือ พรึงลำภู 15 มกราคม 2557.
Looking Ahead to MTN-017 Ross D. Cranston MD, FRCP Microbicide Trials Network IRMA.
MTN-025/HOPE Decliner Population Procedures. Who are the Decliner Population? Former ASPIRE participants who decline or express no interest in joining.
A FRUIT AND VEGETABLE PRESCRIPTION PROGRAM
Planning for HOPE PUEVs and Study Exit Visits
Protocol Deviations.
MAINTAINING THE INVESTIGATOR’S SITE FILE
Protocol References Section Title 6.2 Entry Visit 5.1
Protocol References Section Title 6.2 Entry Visit 5.1
MTN-026 Study Product Considerations
MTN-037 Study Product Considerations
MAINTAINING THE INVESTIGATOR’S STUDY FILE
HOPE STUDY PRODUCT TRAINING
Understanding the Process of Documenting Informed Consent
Module 6: Case Report Form (Chart Abstraction)
Presentation transcript:

1 MTN-003 Study Specific Training Randomization Overview

2 Why Randomize? Ensures that all study groups in a clinical trial are comparable with regard to factors that could affect study outcomes (e.g., risk of HIV infection) –Age and other demographics –Past medical history and pre-existing conditions –Sexual behaviors and condom use Ensures that the study team will be able to clearly interpret the final study results –E.g. If the study drug has an effect in reducing HIV, the effect of the drug is due to the drug itself and not some other factor

3 What Randomization Achieves Active DrugPlacebo Mean Age (yrs) 2122 Mean Education (yrs) 11 Ever Pregnant 85%84% Married 5% Vaginal sex acts in last 7 days 55 Condom use in last 7 days 89%

4 MTN-003 Randomization Scheme All Participants (4200) Oral Tablet (2520) Truvada Tablet (840) Tenofovir Tablet (840) Placebo Tablet (840) Vaginal Gel (1680) Tenofovir Gel (840) Placebo Gel (840) Not Blinded Blinded

5 How Will the Randomization Process Work? Envelope randomization will be used SCHARP will provide two sets of envelopes to each site 1)Clinic Randomization Envelopes 2)Pharmacy Randomization Envelopes Each set of envelopes will be numbered sequentially Each clinic envelope will have a matching pharmacy envelope (matched by envelope number)

6 Each participant will be assigned a clinic randomization envelope and the matching pharmacy randomization envelope (e.g., a participant assigned clinic envelope 0100 will be assigned pharmacy envelope 0100, etc.) Assignment of the clinic envelope is the effective act of enrollment in MTN-003 Once a clinic envelope is assigned, the participant is considered officially enrolled in the study How Will the Randomization Process Work?

7 Importance of Sequential Clinic Envelope Assignment It is critical to the integrity of the study that clinic randomization envelopes are assigned in sequential order –If not assigned in proper order (even just one), this could have a serious impact on validity of study results. SCHARP will provide clinic and pharmacy envelope tracking records to document envelope assignments –This will help ensure that envelopes are assigned sequentially

8 Clinic Envelope Tracking Record

9 Randomization Envelopes Clinic envelopes sent to site clinics Pharmacy envelopes sent to site pharmacies Envelope specifications: –Large enough to contain A4 size paper –Opaque: manila folder inside each envelope –Tamper evident: sealed with blue tape –Labeled as Clinic or Pharmacy with site information, study number, envelope number All envelopes assembled and reviewed for at SCHARP before shipment to sites

10 Clinic Randomization Envelopes Maintained by clinic staff CLINIC MTN 003-Randomization Envelope DAIDS Site ID: CRS Name: R.K. Khan Hospital CRS Location: Durban, South Africa Envelope Number: 0001

11 Pharmacy Randomization Envelopes Maintained by pharmacy staff Look exactly like clinic envelopes, except labeled as PHARMACY PHARMACY MTN-003 Randomization Envelope DAIDS Site ID: CRS Name: R.K. Khan Hospital CRS Location: Durban, South Africa Envelope Number: 0001

12

13

14 Clinic Randomization Envelopes Contain one MTN-003 prescription: –Two-part, no carbon required (NCR) form original (top part) is white copy (bottom part) is yellow –Assignment to Oral Tablets or Vaginal Gel Authorized prescriber or other designated clinic staff should complete information on prescription (e.g., PTID, Date Assigned) Signature of authorized prescriber is required Dispensing instructions for pharmacy staff Once completed, white (original) goes to pharmacy, yellow (copy) is filed, along with opened envelope, in the participant study notebook

15 Gel Prescription

16 Tablet Prescription

17 Pharmacy Randomization Envelopes Contain study product dispensing records that will be completed by pharmacy staff Dispensing records are linked to prescriptions by envelope number –The prescription from the clinic envelope will have the clinic envelope number pre-printed on it –The pharmacy will receive the prescription and assign the pharmacy envelope with this same number to the participant –Pharmacy staff will then dispense the assigned study product to the participant and record this information on the dispensing record.

18 Confirm participants eligibility for the study Complete the enrollment informed consent process Administer the Baseline Behavior Assessment CRF and Baseline ACASI questionnaire Obtain blood for plasma archive If applicable, administer Hepatitis B vaccine Before You Randomize…..

19 SCHARP Monitoring of Randomization Both clinic and pharmacy staff will record randomization information on CRFs and fax these CRFs to SCHARP Based on these CRFs, SCHARP will verify sequential assignment of clinic envelopes and proper random assignment to either oral tablets or vaginal gel SCHARP will also verify that the correct product was dispensed at the Enrollment Visit –SCHARP will monitor on-study dispensing as well

20 SCHARP Monitoring of Randomization If CRF data indicate a randomization error, SCHARP will contact the site clinic and/or pharmacy immediately to verify the information recorded on the CRF If it is determined that a randomization error has occurred, the Protocol Team will be notified and the site will be provided guidance on how to address the error

21 Operational Considerations Each site must establish an MTN-003 SOP for randomization (clinic procedures only) to specify: –Who will receive clinic randomization envelopes from SCHARP –Where clinic randomization envelopes and tracking record will be kept (secure location) –How clinic envelopes will be assigned and who will assign them –Who will complete prescriptions –Where opened envelopes and yellow (clinic) copies of prescriptions will be filed –Who will QA/QC randomization documentation and how often this will occur

22 If the site identifies a randomization error… Immediately contact the MTN-003 SCHARP Project Managers and FHI Clinical Research Managers and explain the situation Follow guidance provided by SCHARP and the Protocol Team –randomizations may need to be halted during this time

23 Questions???